Treatment of Immunoglobulin A (IgA) Nephropathy by Angiotensin-Converting Enzyme (ACE) Inhibitor

Phase 3CompletedNCT00437463

Sanofi60 enrolled

Overview

To evaluate the efficacy of the ACE inhibitor ramipril in the treatment of early IgA nephropathy.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Glomerulonephritis

Interventions

RamiprilDRUG

2.5mg and increase to 5mg if patient do not develop symptomatic hypotension

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * biopsy-confirmed IgA nephropathy * proteinuria less than 0.5 g per day, normal blood pressure, and serum creatinine below 120 µmol/l Exclusion Criteria: * pregnant or nursing mother, or women of childbearing potential without an effective method of birth control * history of myocardial infarction, congestive heart failure, or any other medical indication that necessitate the use of ACE inhibitor * evidence of clinically significant hepatic, gastrointestinal, autoimmune disease * history of malignancy, drug or alcohol abuse * participation in any previous trial on ACE inhibitor * taking other investigational drugs within the past 30 days * known history of sensitivity / allergy to ACE inhibitor The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Locations (1)

Sanofi-Aventis

Hong Kong, Hong Kong

Outcomes

Primary Outcomes

Development of hypertension (defined as blood pressure above 140/90 mm Hg and require anti-hypertensive therapy)